Celyad Oncology SA (CLYYF)
USD 0.53
(-22.44%)
USD 0.53
(-22.44%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -8.44 Million EUR | 79.36% |
| 2022 | -40.93 Million EUR | -54.4% |
| 2021 | -26.51 Million EUR | -51.49% |
| 2020 | -17.5 Million EUR | 38.88% |
| 2019 | -28.63 Million EUR | 21.15% |
| 2018 | -36.31 Million EUR | 35.61% |
| 2017 | -56.39 Million EUR | -138.9% |
| 2016 | -23.6 Million EUR | 18.92% |
| 2015 | -29.11 Million EUR | -76.95% |
| 2014 | -16.45 Million EUR | -33.26% |
| 2013 | -12.34 Million EUR | -473.56% |
| 2012 | -2.15 Million EUR | 76.43% |
| 2011 | -9.13 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -3.04 Million EUR | 0.0% |
| 2023 Q2 | -3.74 Million EUR | 0.0% |
| 2023 Q4 | -4.7 Million EUR | 0.0% |
| 2022 Q4 | -26.87 Million EUR | 0.0% |
| 2022 Q2 | -6.37 Million EUR | 15.4% |
| 2022 Q1 | -7.53 Million EUR | -76.4% |
| 2022 FY | -40.93 Million EUR | -54.4% |
| 2021 Q4 | -4.27 Million EUR | 41.26% |
| 2021 Q2 | -6.12 Million EUR | 29.59% |
| 2021 Q3 | -7.27 Million EUR | -18.69% |
| 2021 Q1 | -8.7 Million EUR | -280.37% |
| 2021 FY | -26.51 Million EUR | -51.49% |
| 2020 Q2 | -16.59 Million EUR | 0.0% |
| 2020 FY | -17.5 Million EUR | 38.88% |
| 2020 Q4 | 4.82 Million EUR | 188.82% |
| 2020 Q3 | -5.43 Million EUR | 67.28% |
| 2019 FY | -28.63 Million EUR | 23.5% |
| 2019 Q1 | -7.15 Million EUR | 62.26% |
| 2019 Q2 | -15.96 Million EUR | -123.04% |
| 2019 Q4 | -12.66 Million EUR | 0.0% |
| 2018 Q2 | -18.45 Million EUR | -96.95% |
| 2018 FY | -37.42 Million EUR | 33.63% |
| 2018 Q4 | -18.96 Million EUR | 0.0% |
| 2018 Q1 | -9.37 Million EUR | 77.67% |
| 2017 FY | -56.39 Million EUR | -138.9% |
| 2017 Q4 | -41.98 Million EUR | 0.0% |
| 2017 Q2 | -14.41 Million EUR | -2.24% |
| 2017 Q1 | -14.09 Million EUR | -111.06% |
| 2016 FY | -23.6 Million EUR | 18.92% |
| 2016 Q2 | -16.92 Million EUR | -186.81% |
| 2016 Q4 | -6.68 Million EUR | 0.0% |
| 2016 Q1 | -5.9 Million EUR | 57.16% |
| 2015 Q4 | -13.77 Million EUR | -88.61% |
| 2015 FY | -29.11 Million EUR | -76.95% |
| 2015 Q3 | -7.3 Million EUR | 52.39% |
| 2015 Q2 | -15.33 Million EUR | -110.02% |
| 2015 Q1 | -7.3 Million EUR | 27.49% |
| 2014 FY | -16.45 Million EUR | -33.26% |
| 2014 Q1 | -4.11 Million EUR | 48.91% |
| 2014 Q4 | -10.07 Million EUR | -144.54% |
| 2014 Q2 | -6.38 Million EUR | -54.93% |
| 2014 Q3 | -4.11 Million EUR | 35.45% |
| 2013 Q1 | -3.19 Million EUR | 0.0% |
| 2013 Q2 | -6.42 Million EUR | -101.31% |
| 2013 Q3 | -3.19 Million EUR | 50.33% |
| 2013 Q4 | -8.06 Million EUR | -152.47% |
| 2013 FY | -12.34 Million EUR | -473.56% |
| 2012 Q3 | -538.13 Thousand EUR | 0.0% |
| 2012 Q2 | -538.13 Thousand EUR | 0.0% |
| 2012 Q1 | -538.13 Thousand EUR | 0.0% |
| 2012 FY | -2.15 Million EUR | 76.43% |
| 2012 Q4 | -3.19 Million EUR | -493.33% |
| 2011 Q1 | -2.28 Million EUR | 0.0% |
| 2011 Q2 | -2.28 Million EUR | 0.0% |
| 2011 Q3 | -2.28 Million EUR | 0.0% |
| 2011 Q4 | -538.13 Thousand EUR | 76.43% |
| 2011 FY | -9.13 Million EUR | 0.0% |
| 2010 Q4 | -2.28 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 52.97 Million USD | 115.946% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -20.982% |
| CSL Limited | 2.64 Billion USD | 100.32% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 112.97% |
| Regen BioPharma, Inc. | 1.02 Million USD | 925.397% |
| BioStem Technologies, Inc. | -8.48 Million USD | 0.412% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -121.21% |
| Qrons Inc. | -789.34 Thousand USD | -970.252% |
| Nascent Biotech, Inc. | -2.08 Million USD | -304.659% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 86.505% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -6.895% |
| Skye Bioscience, Inc. | -37.64 Million USD | 77.559% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1933.316% |
| Rebus Holdings, Inc. | -1.02 Million USD | -728.235% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 46.772% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -532.605% |
| Genscript Biotech Corporation | -95.47 Million USD | 91.152% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1235.849% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 88.73% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -28.465% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -2989.955% |
| SQZ Biotechnologies Company | -79.46 Million USD | 89.369% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -192.076% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -364.041% |
| Mesoblast Limited | -87.95 Million USD | 90.395% |
| Marizyme, Inc. | -65.34 Million USD | 87.072% |
| Genus plc | 7.9 Million USD | 206.937% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 22.437% |
| Pharming Group N.V. | -10.54 Million USD | 19.909% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -289.342% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -127.695% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 4.478% |
| ContraFect Corporation | -65.15 Million USD | 87.034% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -72.9% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -389.043% |
| IMV Inc. | -36.48 Million USD | 76.846% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -4.818% |
| MultiCell Technologies, Inc. | -380.07 USD | -2222648.441% |
| ONE Bio Corp. | 8.67 Million USD | 197.365% |
| Accustem Sciences Inc. | -3.74 Million USD | -125.495% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 83.657% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -566.701% |
| Q BioMed Inc. | -2.05 Million USD | -311.677% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -126.306% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -254.828% |
| Biomind Labs Inc. | -1.21 Million USD | -595.699% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 85.855% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -172.361% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -333.398% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -56310.256% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -45.223% |
| GB Sciences, Inc. | -1.36 Million USD | -520.411% |
| Alpha Cognition Inc. | -13.77 Million USD | 38.661% |
| HST Global, Inc. | -146.21 Thousand USD | -5677.991% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -381.43% |
| Halberd Corporation | -79.67 Thousand USD | -10502.942% |
| Enzolytics Inc. | -2.17 Million USD | -288.087% |
| Agentix Corp. | -1.37 Million USD | -514.753% |
| Resverlogix Corp. | -3.61 Million USD | -134.017% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -166.378% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 97.137% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 8720.408% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 222.0% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -112.636% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -179.168% |
| AVAX Technologies, Inc. | -6.41 Million USD | -31.719% |
| Zenith Capital Corp. | -10.59 Million USD | 20.272% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -36247.991% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -103.766% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -13877.357% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -321.322% |
| Kadimastem Ltd | -3.3 Million USD | -155.427% |
| Helix BioMedix, Inc. | -1.05 Million USD | -699.957% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1814.045% |
| LadRx Corporation | 400.44 Thousand USD | 2209.664% |
| Cell Source, Inc. | -5.32 Million USD | -58.761% |
| Regen BioPharma, Inc. | 1.02 Million USD | 925.397% |
| NovAccess Global Inc. | -4.76 Million USD | -77.137% |
| Affymax, Inc. | -14.42 Million USD | 41.431% |
| Itoco Inc. | -1.86 Million USD | -352.008% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -90.162% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -406.171% |
| Mobile Lads Corp. | -2.26 Million USD | -273.262% |
| CytoDyn Inc. | -49.84 Million USD | 83.05% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -10589.206% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -3603.2% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -797.264% |
| SYBLEU INC | -180.3 Thousand USD | -4585.42% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -423.83% |
| International Stem Cell Corporation | -131 Thousand USD | -6348.855% |
| Bioxytran, Inc. | -4.28 Million USD | -97.383% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -15466.038% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -233.88% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 82.426% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -299.622% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -981.847% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -166.667% |
| Neutra Corp. | -233.46 Thousand USD | -3518.53% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 58.366% |
| PureTech Health plc | -65.69 Million USD | 87.141% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 60.276% |
| IXICO plc | -1.17 Million USD | -617.148% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 14.899% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 85.212% |
| CSL Limited | 2.64 Billion USD | 100.32% |
| Cellectis S.A. | -103.17 Million USD | 91.812% |